| Market Capitalization (Millions $) |
10 |
| Shares
Outstanding (Millions) |
5 |
| Employees |
116 |
| Revenues (TTM) (Millions $) |
2 |
| Net Income (TTM) (Millions $) |
-40 |
| Cash Flow (TTM) (Millions $) |
-43 |
| Capital Exp. (TTM) (Millions $) |
0 |
Bioxcel Therapeutics Inc
Bioxcel Therapeutics Inc. is a clinical-stage biopharmaceutical company that uses artificial intelligence (AI) and machine learning (ML) to identify potential neurological and immuno-oncological therapies. The company was founded in 2017 and is headquartered in New Haven, Connecticut, with additional offices in San Francisco, California, and Noida, India.
The company's AI-based approach involves analyzing large data sets of genetic, clinical, and pharmacological information to identify potential drug candidates for specific diseases. The platform uses algorithms to predict the efficacy of the drug candidate, potential side effects, and patient selection criteria for clinical trials.
Bioxcel's lead drug candidate, BXCL501, is a sublingual thin film formulation of dexmedetomidine that is being developed for the treatment of agitation in patients with schizophrenia and bipolar disorder. The drug has shown promising results in Phase 1b/2 clinical trials, with significant reductions in agitation and anxiety in patients.
The company's second drug candidate, BXCL701, is a small molecule immune activator being developed for the treatment of various types of cancer. The drug has shown potential in preclinical studies to enhance the immune system's ability to recognize and attack cancer cells.
Bioxcel has also partnered with leading pharmaceutical companies such as Pfizer and Urovant Sciences to develop and commercialize its pipeline of neurology and oncology drugs.
In addition to its drug development efforts, Bioxcel is also focused on building a data-driven approach to patient identification and recruitment for clinical trials. The company is using its AI platform to identify patient populations that are most likely to benefit from its therapies and to optimize clinical trial design and execution.
Overall, Bioxcel Therapeutics is a biopharmaceutical company that is leveraging AI and ML to develop innovative therapies for neurological and immuno-oncological diseases. The company's unique approach to drug development and patient identification has the potential to significantly improve patient outcomes and accelerate the drug development process.
Company Address: 555 Long Wharf Drive New Haven 6511 CT
Company Phone Number: 238-6837 Stock Exchange / Ticker: NASDAQ BTAI
|
100 %